Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist.

The human immunodeficiency virus-1 (HIV-1) trans-activator Tat is an attractive target for the development of antiviral drugs because inhibition of Tat would arrest the virus at an early stage. The drug Ro 5-3335 [7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepine-2(H)-one], inhibited gene expression by HIV-1 at the level of transcriptional trans-activation by Tat. The compound did not inhibit the basal activity of the promoter. Both Tat and its target sequence TAR were required for the observed inhibitory activity. Ro 5-3335 reduced the amount of cell-associated viral RNA and antigen in acutely, as well as in chronically infected cells in vitro (median inhibition concentration 0.1 to 1 micromolar). Effective inhibition of viral replication was also observed 24 hours after cells were transfected with infectious recombinant HIV-1 DNA. The compound was active against both HIV-1 and HIV-2 and against 3'-azido-3'-deoxythymidine (AZT)-resistant clinical isolates.

[1]  S. Arya,et al.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). , 1985, Science.

[2]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[3]  B. Berkhout,et al.  trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis , 1989, Journal of virology.

[4]  S. Salahuddin,et al.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.

[5]  M. Mathews,et al.  HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation , 1989, Cell.

[6]  K. Karjalainen,et al.  Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.

[7]  J. Sodroski,et al.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication , 1986, Cell.

[8]  P. Luciw,et al.  Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[10]  Michael B. Mathews,et al.  Transcriptional but not translational regulation of HIV-1 by the tat gene product , 1988, Nature.

[11]  F. Wong-Staal,et al.  Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1. , 1988, Science.

[12]  B. Cullen,et al.  Regulatory pathways governing HIV-1 replication , 1989, Cell.

[13]  S. Dewhurst,et al.  Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual , 1988, Journal of virology.

[14]  D. Volsky,et al.  A human T-cell line resistant to cytopathic effects of the human immunodeficiency virus (HIV). , 1987, Virology.

[15]  M. Gonda,et al.  The trans-activator gene of HTLV-III is essential for virus replication , 1986, Nature.

[16]  D. Baltimore,et al.  Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells. , 1988, Science.

[17]  P. Luciw,et al.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. , 1989, Genes & development.

[18]  P. Luciw,et al.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product , 1987, Nature.

[19]  A. Frankel,et al.  Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. , 1989, Science.

[20]  D. Baltimore,et al.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Cullen,et al.  Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat , 1988, Journal of virology.

[22]  B. Cullen,et al.  Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. , 1988, Gene.

[23]  Eric C. Holland,et al.  HIV-1 tat trans-activation requires the loop sequence within tar , 1988, Nature.

[24]  L. Montagnier,et al.  Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo. , 1990, The Journal of infectious diseases.

[25]  R. Siliciano,et al.  Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion , 1988, Cell.

[26]  D. Richman,et al.  Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro , 1989, The Journal of experimental medicine.

[27]  J. Sodroski,et al.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. , 1985, Science.

[28]  D. Volsky,et al.  Titration of human immunodeficiency virus type 1 (HIV-1) and quantitative analysis of virus expression in vitro using liquid RNA-RNA hybridization. , 1990, Journal of virological methods.

[29]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[30]  J. Sodroski,et al.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat , 1985, Cell.

[31]  B. Berkhout,et al.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target , 1989, Cell.

[32]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.